Repligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference
May 24 2017 - 7:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that
management will participate in the 14th Annual Craig-Hallum
Institutional Investor Conference, to be held in Minneapolis on
Wednesday, May 31, 2017.
About Repligen CorporationRepligen Corporation
(NASDAQ:RGEN) is a bioprocessing company focused on the
development, manufacture and commercialization of highly innovative
products used to improve the biological drug manufacturing process.
Our portfolio includes Protein products (Protein A affinity
ligands, cell culture growth factors), Chromatography products
(OPUS® pre-packed columns, chromatography resins, ELISA kits) and
Filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF
cassettes). Our bioprocessing products are sold to major life
sciences companies, biopharmaceutical development companies and
contract manufacturing organizations worldwide. We are the leading
manufacturer of Protein A ligands, a critical component of Protein
A resins that are the industry standard for downstream separation
and purification of monoclonal antibody-based therapeutics. Our
growth factors are a key component of cell culture media used in
upstream processes to accelerate cell growth and productivity in a
bioreactor. Our innovative line of OPUS® chromatography columns,
used in downstream processes for bench-scale through clinical-scale
purification needs, are delivered pre-packed with our customers’
choice of resin and bed height. Our XCell™ ATF Systems, available
in stainless steel and single-use configurations, continuously
eliminate waste from a bioreactor to concentrate cells in upstream
processes. TangenX Sius™ TFF single-use cassettes and hardware are
used for biologic drug concentration in downstream formulation
processes. Repligen’s corporate headquarters are in Waltham, MA
(USA) and our manufacturing facilities are located in Waltham, MA,
Shrewsbury, MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Contact:
Sondra Newman
snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024